Background Evidence on overall survival (OS) with cyclin‐dependent kinase 4 and 6
(CDK4/6) inhibitors is generally limited to data from clinical trials or a few observational …

Abstract Purpose Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have improved patient
survival in hormone receptor-positive/human epidermal growth factor receptor 2-negative …

De novo metastatic breast cancer (dnMBC) accounts for~ 6–10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …

Abstract Heat shock factor 1 (HSF1), a key regulator of transcriptional responses to
proteotoxic stress, was linked to estrogen (E2) signaling through estrogen receptor α (ERα) …

Background There are few studies on surgical management in patients with de novo
metastatic inflammatory breast cancer (IBC). The objective of this study is to examine the …

Purpose Many patients with metastatic cancer live years beyond diagnosis, and there
remains a need to improve the therapeutic ratio of metastasis-directed radiation for these …

Purpose Though less than 5% of patients with breast cancer present with De Novo
Metastasis (dnMBC) in Western societies, this percentage may reach 30% in developing …

To determine the course of treatment while considering the patients' desires, we examined
trends regarding patients' perception and expectations over the course of cancer …

A combination of improvements in patient survival, increasing treatment duration, and the
development of more expensive agents has led to a doubling of per-capita spending on …

Breast cancer is a heterogeneous disease, so treatment and prognosis depend on tumor
subtype, grade, lymph node status and stage of disease; however even patients with similar …